Cargando…

FcRn inhibitors: a novel option for the treatment of myasthenia gravis

Myasthenia gravis is an acquired, humoral immunity-mediated autoimmune disease characterized by the production of autoantibodies that impair synaptic transmission at the neuromuscular junction. The intervention-mediated clearance of immunoglobulin G (IgG) was shown to be effective in controlling the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Li-Na, Hou, Hai-Man, Wang, Sai, Zhang, Shuang, Wang, Ge-Ge, Guo, Zi-Yan, Wu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154512/
https://www.ncbi.nlm.nih.gov/pubmed/36751773
http://dx.doi.org/10.4103/1673-5374.363824

Ejemplares similares